Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VisualSonics, a developer of high-frequency micro-ultrasound imaging systems, and Seno Medical Instruments, a developer of medical devices for early detection of cancer, have signed a licensing agreement providing VisualSonics exclusive rights to Seno Medical's opto-acoustic technology for preclinical research.
Subscribe to our email newsletter
VisualSonics will embed Seno’s opto-acoustic technology in its next generation of high-frequency ultrasound platforms and this will extend their molecular imaging capability to the sub cellular level. This combination will drive the new molecular imaging utility for the next generation of preclinical imaging with the Vevo platform, the two companies said.
VisualSonics has licensed Seno Medical Instrument’s opto-acoustic imaging technology to enable researchers to non-invasively detect and monitor biological structures, functions and processes at the cellular and molecular level.
Tom Little, president and CEO of VisualSonics, said: “The application of opto-acoustic technology to our Vevo preclinical imaging platform is an exciting new area for VisualSonics. We will be enabling researchers to push the limits of discovery as we develop tools for intracellular and molecular imaging with VisualSonics technology and Seno Medical IP.”